SGLT2 Inhibitors
Sort by:
The North American Thrombosis Forum (NATF)
Novel Trials and Guideline Updates from the 2020 ESC Congress: When to Use Empagliflozin, Dapagliflozin and Antiarrhythmic Drugs? What Are the Guidelines for Patients with AFib and Elective PCI or ACS? When to Perform Catheter Ablation?
FEATURING
Christian Cruff
- 596 views
- October 15, 2020
- 6
Houston Methodist DeBakey Heart and Vascular Center
How to Identify and Intervene on Heart Failure Risk Factors?
FEATURING
Sadiya Khan
- 376 views
- November 25, 2020
- 3
John Tayek
2020 Updates on Insulin Therapy: What Are the Current ADA Standards of Care?
- 2,466 views
- November 25, 2020
- 13
John Tayek
2020 Updates on ADA Standard of Care: Managing Injectable Therapy and Cardiovascular Risk
- 1,077 views
- November 25, 2020
- 6
Naveed Sattar
Can Empagliflozin Successfully Treat T2D Whilst Preventing Heart Failure and Protecting Renal Function?
- 819 views
- November 25, 2020
- 3
Christos Argyropoulos
Diabetic Kidney Disease Treatment: When to Use SGLT2 Inhibitors & Who Should Prescribe Them?
- 1,256 views
- December 14, 2020
- 3
26th Annual San Diego Heart Failure Symposium
SGLT2 Inhibitors and GLP-1 Receptor Agonists for Treating Type 2 Diabetes and Reducing Cardiovascular Risk
FEATURING
Pam Taub
- 893 views
- December 16, 2020
- 3
26th Annual San Diego Heart Failure Symposium
Effects of SGLT2 Inhibitors in Treating Heart Failure Patients Regardless of Their Glycemic Status
FEATURING
Gregg Fonarow
- 255 views
- December 16, 2020
- 2
26th Annual San Diego Heart Failure Symposium
Q&A: Advances in Heart Failure Management
- 25 views
- December 17, 2020
Keck School of Medicine of USC
Newer Therapies in Management of Chronic Heart Failure: Roles of SGLT2 Inhibitors and Vericiguat
FEATURING
Kruti Pandya
- 290 views
- December 28, 2020
Scripps Health: 2020 Updates in Diabetes Management
Update on SGLT2i in Diabetic Kidney Disease: How Effective Are Canagliflozin & Dapagliflozin?
FEATURING
Kim Harper
- 541 views
- January 25, 2021
- 5
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?
FEATURING
Barry Greenberg
- 2,010 views
- February 5, 2021
- 22
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Approaches to Treating Diabetes that Reduce CV Events: How Effective Are DPP-4 Inhibitors, GLP1-Receptor Agonists and SGLT-2 Inhibitors in Reducing MACE and Preventing HF Events?
FEATURING
Jia Shen
- 337 views
- February 5, 2021
- 4
16th Annual Heart Failure Holiday Symposium
New Treatment Approaches to HFrEF: When to Use SGLT2, Vericiguat, Omecamtiv Mecarbil and IV Iron?
FEATURING
Mark Drazner
- 1,116 views
- February 18, 2021
- 12